Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic AAA stent grafts

This article was originally published in The Gray Sheet

Executive Summary

Xcelerant delivery system earns CE mark for use with Talent abdominal aortic aneurysm stent graft. The system features improved catheter material and an integrated deployment handle to enhance trackability, aid kink resistance and decrease deployment force, resulting in reduced implant procedure times, Medtronic says. The company also launches "higher density" Resilient graft material for its U.S. AAA stent graft, the AneuRx. The material aims to "reduce porosity and improve durability," the firm explains July 14. Medtronic's AAA announcements follow controversy over an FDA-authored article about AneuRx safety data that was retracted from a peer-review journal after Medtronic threatened litigation over use of proprietary clinical data (1"The Gray Sheet" July 12, 2004, p. 29)...

You may also be interested in...



Medtronic Stands Behind Proprietary Nature Of AneuRx Clinical Data

AdvaMed's intent to craft a position on the release of proprietary data generated by manufacturers during clinical trials should gain momentum from recently publicized study data on Medtronic's AneuRx device

Can Synthetic CBD Overcome Cannabis Stigma And Break EU Novel Foods Deadlock?

Czech firm CBDepot has filed a novel food application for synthetically made CBD in Europe, which it hopes regulators will find more palatable than those for supplements derived from the cannabis plant.

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

UsernamePublicRestriction

Register

MT020587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel